The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration. A Systematic Review of the Literature and Meta-analysis

Ophthalmology

Volumn 115, Issue 1, 2008, Pages

  Wong, Tien ^a   Chakravarthy, Usha ^b   Klein, Ronald ^c   Mitchell, Paul ^d   Zlateva, Gergana ^e   Buggage, Ronald ^e   Fahrbach, Kyle ^f   Probst, Corey ^f   Sledge, Isabella ^f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e PFIZER INC   (United States)

^f UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SYSTEMATIC REVIEW; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 37449010146     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.03.008     Document Type: Article

References (94)

1. Kahn H.A., Leibowitz H.M., Ganley J.P., et al. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 106 (1977) 17-32
2. Klaver C.C., Wolfs R.C., Vingerling J.R., et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 116 (1998) 653-658
3. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122 (2004) 564-572
4. Smith W., Assink J., Klein R., et al. Risk factors for age-related macular dgeneration: pooled findings from three continents. Ophthalmology 108 (2001) 697-704
5. Guyer D.R., Fine S.L., Maguire M.G., et al. Subfoveal choroidal neovascular membranes in age-related macular degeneration: visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol 104 (1986) 702-705
6. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 108 (1990) 816-824
7. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 111 (1993) 1200-1209
8. Argon laser photocoagulation for senile macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 100 (1982) 912-918
9. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 117 (1999) 1329-1345
10. Margherio R.R., Margherio A.R., and DeSantis M.E. Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina 20 (2000) 325-330
11. Olsen T.W., Feng X., Kasper T.J., et al. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 111 (2005) 250-255
12. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 131 (2001) 541-560
13. QLT Inc. Visudyne in Occult (VIO) Trial to continue to its conclusion at 24 months. [press release]. October 14 (2004). http://www.qltinc.com/Qltinc/pages/pagespressdetail.cfm?PressID=224& InternetPageID=31&YearRange=2004&Type=Current&Criteria=visud yne&cr=5&vc=PressReleases Accessed September 5, 2006
14. QLT Inc. QLT announces two year results of Visudyne in Occult (VIO) Trial. [press release]. September 20 (2005). http://www.qltinc.com/Qltinc/pages/pagespressdetail.cfm?PressID=252& YearRange=2005&InternetPageID=31 Accessed September 20, 2005
15. Radiation Therapy for Age-Related Macular Degeneration Study Group. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Ophthalmology 106 (1999) 2239-2247
16. Lim J.I. Macular degeneration: the latest in current medical management. Retina 26 suppl (2006) S17-S20
17. Pauleikhoff D. Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina 25 (2005) 1065-1084
18. Bressler S.B., Pieramici D.J., Koester J.M., and Bressler N.M. Natural history of minimally classic subfoveal choroidal neovascular lesions in the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) investigation: outcomes potentially relevant to management-TAP report no. 6. Arch Ophthalmol 122 (2004) 325-329
19. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report no. 3. Arch Ophthalmol 120 (2002) 1443-1454
20. Arnold J., Algan M., Soubrane G., et al. Indirect scatter laser photocoagulation to subfoveal choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 235 (1997) 208-216
21. Atmaca L.S., Ozmert E., and Idil A. Natural progression of age-related macular degeneration. Ann Ophthalmol 25 (1993) 412-417
22. Avery R.L., Fekrat S., Hawkins B.S., and Bressler N.M. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 16 (1996) 183-189
23. Baumal C.R., Reichel E., Duker J.S., et al. Indocyanine green hyperfluorescence associated with serous retinal pigment epithelial detachment in age-related macular degeneration. Ophthalmology 104 (1997) 761-769
24. Baun O., Vinding T., and Krogh E. Natural course in fellow eyes of patients with unilateral age-related exudative maculopathy: a fluorescein angiographic 4-year follow-up of 45 patients. Acta Ophthalmol (Copehn) 71 (1993) 398-401
25. Bergink G.J., Hoyng C.B., van der Maazen R.W., et al. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefes Arch Clin Exp Ophthalmol 236 (1998) 321-325
26. Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology 111 (2004) 1993-2006
27. Bressler N.M., Frost L.A., Bressler S.B., et al. Natural course of poorly defined choroidal neovascularization associated with macular degeneration. Arch Ophthalmol 106 (1988) 1537-1542
28. Bressler N.M., Maguire M.G., Murphy P.L., et al. Macular scatter ("grid") laser treatment of poorly demarcated subfoveal choroidal neovascularization in age-related macular degeneration: results of a randomized pilot trial. Arch Ophthalmol 114 (1996) 1456-1464
29. Bressler S.B., Bressler N.M., Fine S.L., et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 93 (1982) 157-163
30. Char D.H., Irvine A.I., Posner M.D., et al. Randomized trial of radiation for age-related macular degeneration. Am J Ophthalmol 127 (1999) 574-578
31. Ciulla T.A., Danis R.P., Klein S.B., et al. Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. Am J Ophthalmol 134 (2002) 905-906
32. Coscas G., Soubrane G., Ramahefasolo C., and Fardeau C. Perifoveal laser treatment for subfoveal choroidal new vessels in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 109 (1991) 1258-1265
33. Danis R.P., Ciulla T.A., Pratt L.M., and Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20 (2000) 244-250
34. Eisner A., Klein M.L., Zilis J.D., and Watkins M.D. Visual function and the subsequent development of exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 33 (1992) 3091-3102
35. Engler C., Sander B., Villumsen J., and Lund-Andersen H. Interferon alfa-2a modifies the course of subfoveal and juxtafoveal choroidal neovascularization. Br J Ophthalmol 78 (1994) 749-753
36. Gillies M.C., Simpson J.M., Luo W., et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121 (2003) 667-673
37. Gudnadottir G.S., Magnusson K.P., Stefansson E., et al. The time pattern of bilateral exudative age-related macular degeneration. Acta Ophthalmol Scand 83 (2005) 333-336
38. Hart P.M., Chakravarthy U., MacKenzie G., et al. Teletherapy for subfoveal choroidal neovascularisation of age-related macular degeneration: results of follow up in a non-randomised study. Br J Ophthalmol 80 (1996) 1046-1050
39. Hart P.M., Chakravarthy U., MacKenzie G., et al. Visual outcomes in the Subfoveal Radiotherapy Study: a randomized controlled trial of teletherapy for age-related macular degeneration. Arch Ophthalmol 120 (2002) 1029-1038
40. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings. SST report no. 11. Ophthalmology 111 (2004) 1967-1980
41. Jaakkola A., Heikkonen J., Tommila P., et al. Strontium plaque brachytherapy for exudative age-related macular degeneration. Three-year results of a randomized study. Ophthalmology 112 (2005) 567-573
42. Jonas J.B., Degenring R.F., Kreissig I., et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide: a prospective comparative nonrandomized study. Eye 19 (2005) 163-170
43. Jonas J.B., Spandau U.H., Harder B., et al. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 139 (2005) 1073-1079
44. Kobayashi H., and Kobayashi K. Age-related macular degeneration: long-term results of radiotherapy for subfoveal neovascular membranes. Am J Ophthalmol 130 (2000) 617-635
45. AMDRT Research Group. The Age-Related Macular Degeneration Radiotherapy Trial (AMDRT): one year results from a pilot study. Am J Ophthalmol 138 (2004) 818-828
46. Marcus D.M., Sheils W., Johnson M.H., et al. External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial. Arch Ophthalmol 119 (2001) 171-180
47. Moorfields Macular Study Group. Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. Br J Ophthalmol 66 (1982) 745-753
48. Oliver-Fernandez A., Bakal J., Segal S., et al. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol 40 (2005) 313-319
49. Papadaki T., Tsilimbaris M., Thermos K., et al. The role of lanreotide in the treatment of choroidal neovascularization secondary to age-related macular degeneration: a pilot clinical trial. Retina 23 (2003) 800-807
50. Parodi M.B., Toto L., Mastropasqua L., et al. Prismatic correction in patients affected by age-related macular degeneration. Clin Rehabil 18 (2004) 828-832
51. Pauleikhoff D., Radermacher M., Spital G., et al. Visual prognosis of second eyes in patients with unilateral late exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 240 (2002) 539-542
52. Pece A., Bolognesi G., Introini U., et al. Indocyanine green angiography of well-defined plaque choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 118 (2000) 630-634
53. Sandberg M.A., Weiner A., Miller S., and Gaudio A.R. High-risk characteristics of fellow eyes of patients with unilateral neovascular age-related macular degeneration. Ophthalmology 105 (1998) 441-447
54. Saric B., Sikic J., Katusic D., and Vukojevic N. Brachytherapy-optional treatment for choroidal neovascularization secondary to age-related macular degeneration. Coll Antropol 25 suppl (2001) 89-96
55. Sarraf D., Gin T., Yu F., et al. Long-term drusen study. Retina 19 (1999) 513-519
56. Schneider U., Gelisken F., and Inhoffen W. Natural course of occult choroidal neovascularization in age-related macular degeneration: development of classic lesions in fluorescein angiography. Acta Ophthalmol Scand 83 (2005) 141-147
57. Scupola A., Coscas G., Soubrane G., and Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 213 (1999) 97-102
58. Sharma S., Bakal J., Oliver-Fernandez A., and Blair J. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration: results of an effectiveness study. Arch Ophthalmol 122 (2004) 853-856
59. Singerman L.J., and Stockfish J.H. Natural history of subfoveal pigment epithelial detachments associated with subfoveal or unidentifiable choroidal neovascularization complicating age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 227 (1989) 501-507
60. Soubrane G., Coscas G., Francais C., and Koenig F. Occult subretinal new vessels in age-related macular degeneration: natural history and early laser treatment. Ophthalmology 97 (1990) 649-657
61. Strahlman E.R., Fine S.L., and Hillis A. The second eye of patients with senile macular degeneration. Arch Ophthalmol 101 (1983) 1191-1193
62. Stur M., Tittl M., Reitner A., and Meisinger V. Oral zinc and the second eye in age-related macular degeneration. Invest Ophthalmol Vis Sci 37 (1996) 1225-1235
63. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen: short-term effects seen in a pilot randomized clinical trial. Ophthalmology 105 (1998) 11-23
64. Uyama M., Takahashi K., Ida N., et al. The second eye of Japanese patients with unilateral exudative age related macular degeneration. Br J Ophthalmol 84 (2000) 1018-1023
65. Yassur Y., Axer-Siegel R., Cohen S., et al. Treatment of neovascular senile maculopathy at the foveal capillary free zone with red krypton laser. Retina 2 (1982) 127-133
66. Stevens T.S., Bressler N.M., Maguire M.G., et al. Occult choroidal neovascularization in age-related macular degeneration: a natural history study. Arch Ophthalmol 115 (1997) 345-350
67. Bressler S.B., Bressler N.M., Fine S.L., et al. Subfoveal neovascular membranes in senile macular degeneration: relationship between membrane size and visual prognosis. Retina 3 (1983) 7-11
68. Jonas J.B., Akkoyun I., Budde W.M., et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 122 (2004) 218-222
69. Macular Photocoagulation Study Group. Occult choroidal neovascularization: influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol 114 (1996) 400-412
70. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. Arch Ophthalmol 112 (1994) 500-509
71. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol 112 (1994) 480-488
72. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 109 (1991) 1220-1231
73. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 109 (1991) 1109-1114
74. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch Ophthalmol 104 (1986) 694-701
75. Schmidt-Erfurth U.M., Elsner H., Terai N., et al. Effects of verteporfin therapy on central visual field function. Ophthalmology 111 (2004) 931-939
76. Verteporfin in Photodynamic Therapy Study Group. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group, Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136 (2003) 407-418
77. Schmidt-Erfurth U.M., and Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology 110 (2003) 1306-1314
78. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 119 (2001) 198-207
79. Bellmann C., Unnebrink K., Rubin G.S., et al. Visual acuity and contrast sensitivity in patients with neovascular age-related macular degeneration: results from the Radiation Therapy for Age-Related Macular Degeneration (RAD-) Study. Graefes Arch Clin Exp Ophthalmol 241 (2003) 968-974
80. Verteporfin in Photodynamic Therapy Study Group. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group, Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report no. 2. Arch Ophthalmol 121 (2003) 1253-1268
81. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia and verteporfin: 1-year results of a randomized clinical trial-VIP report number 1. Ophthalmology 108 (2001) 841-852
82. Centre for Evidence-Based Medicine. Oxford Centre for Evidence-Based Medicine levels of evidence (May 2001). http://www.cebm.net/downloads/Oxford_CEBM_Levels_5.rtf Accessed April 7, 2006
83. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
84. Ahn S.J., Legge G.E., and Luebker A. Printed cards for measuring low-vision reading speed. Vision Res 35 (1995) 1939-1944
85. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
86. Klein R., Klein B.E., Jensen S.C., and Meuer S.M. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 104 (1997) 7-21
87. Mitchell P., Smith W., Attebo K., and Wang J.J. Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study. Ophthalmology 102 (1995) 1450-1460
88. Gragoudas E.S., Adamis A.P., Cunningham E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
89. Shah A.R., and Del Priore L.V. Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots. Am J Ophthalmol 143 (2007) 83-89
90. Bennett S.R., Folk J.C., Blodi C.F., and Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 190 (1990) 33-37
91. Uyama M. Choroidal neovascularization: experimental and clinical study. [in Japanese]. Nippon Ganka Gakkai Zasshi 95 (1991) 1145-1180
92. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 115 (1997) 741-747
93. Schoeppner G., Chuang E.L., and Bird A.C. The risk of fellow eye visual loss with unilateral retinal pigment epithelial tears. Am J Ophthalmol 108 (1989) 683-685
94. Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS). AREDS report no. 19. Ophthalmology 112 (2005) 533-539